Article citationsMore>>

R. L. Souhami, A. W. Craft, J. W. Van der Eijken, M. Nooij, et al., “Randomised Trial of Two Regimens of Chemotherapy in Operable Osteosarcoma: A Study of the European Osteo-sarcoma Intergroup,” Lancet, Vol. 350, No. 9082, 1997, pp. 911-917. doi:10.1016/S0140-6736(97)02307-6

has been cited by the following article:

• TITLE: Role of Neo-Adjuvant Chemotherapy in the Treatment of Osteosarcoma

  AUTHORS: Ranadeb Bandyopadhyay, Arindam Mukherjee, Bishan Basu

  KEYWORDS: Osteosarcoma; Amputation; Neo-Adjuvant Chemotherapy; Adjuvant Chemotherapy

  JOURNAL NAME: Open Journal of Orthopedics, Vol.2 No.2, June 22, 2012

  ABSTRACT: Osteosarcoma is a tumour characterized by the production of osteoid by malignant cells. The incidence is approximately 1 to 3 million/year. The incidence is slightly higher in males. Onset can occur at any age; however, primary high grade osteosarcoma usually occurs in the second decade of life. Historically patients with osteosarcoma were treated with immediate wide or radical amputation. Despite the treatment, 80% patients with apparently isolated disease died of distant metastases. In recent years the number of patients with osteosarcoma of the limb treated by amputation + chemotherapy has increased. In our study, we divided the patients into two groups. One group (A) was treated with amputation + adjuvant chemotherapy. The other group (B) was treated with neo-adjuvant chemotherapy + amputation followed by adjuvant-chemotherapy. In our study, the margin negativity in post surgical specimen was significantly higher (P-value 0.0007) for the group treated with neo-adjuvant chemotherapy. Local recurrence in the group treated without neoadjuvant chemotherapy was significantly more (P-value 0.0005).The systemic recurrence at the end of 6 months was higher the group treated without neoadjuvant chemotherapy (P-value 0.0169).However systemic recurrence between 6 months -1 year and 1 year - 2 years were not significant(P-values 0.1501 and 0.4902). From the above figures it may be concluded that treatment with neo-adjuvant chemotherapy + amputation + adjuvant chemotherapy had definite advantages over upfront amputation + adjuvant chemotherapy.)